^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Tepmetko (tepotinib) (c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ELCC 2023
    Title:

    199P - Suppression of mutant Kirsten-RAS (KRAS G12C) non-small cell lung cancer (NSCLC) resistance to KRAS G12C inhibitors by dual inhibition of hepatocyte growth factor receptor (MET )and V-ATPase.

    Published date:
    03/23/2023
    Excerpt:
    Pretreatment with omeprazole + tepotinib shows broad-spectrum tumor shrinkage in KRAS G12C sensitive and resistant to sotorasib (H358, H23) and in KRAS non-G12C cell lines (A549, H460).
    Secondary therapy:
    omeprazole